MICRODOSES

	microd

MICROD.

Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms.

 

According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice.

There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized.

In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers.

We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%).

We also show parallels between benefits and drawbacks and discuss the implications of these results.

We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report.

Conclusions

These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research.

The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated.

Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought.

This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come.

Introduction

The practice of microdosing psychedelics involves ingesting sub-hallucinogenic amounts of a psychedelic substance (e.g. LSD, psilocybin) and has recently grown in popularity.

The number of popular media accounts and book-length treatments of microdosing has been growing.

Online microdosing communities have grown to the tens of thousands with more than 40,000 users subscribing to the /r/microdosing subreddit (/r/microdosing subreddit, Reddit Inc, San Francisco, CA, USA).

This public interest speaks to a social need for scientific studies to inform the public about the effects of microdosing.

Initial scientific investigations of microdosing are just beginning (Rosenbaum D, Weissman C, Hapke E, Hui K, Petranker R, Dinh-Williams L-A, et al.: Microdosing psychedelic substances: demographics, psychiatric comorbidities, and comorbid substance use, in preparation) and future directions remain unclear.

While full-dose psychedelic research is growing in prominence and outcomes from full-dose studies can certainly inform microdosing studies, focusing solely on known full-dose outcomes could result in missing unanticipated benefits and challenges specific to microdosing.

As such, beginning with an open, exploratory approach could result in a better understanding of the potential benefits and challenges specific to microdosing.

The present study aims to provide a data-driven taxonomy describing the positive and negative experiences reported by microdosers from an open-ended analysis of microdosing-specific outcomes, summarizing high-potential avenues for focused experimental investigations.

The benefits of full-dose psychedelics

While more than a thousand early studies linked psychedelic use with beneficial effects , there was a 40-year pause on psychedelic research following the prohibition of these substances.

Despite continued prohibition, modern research has revealed the promising potential of LSD and psilocybin for treating alcohol and tobacco dependence depression and end-of-life anxiety, while related research on 3,4-methylenedioxymethamphetamine (MDMA) has shown great promise for treating post-traumatic stress disorder.

Psychedelics can also increase openness and occasion mystical-type experiences in healthy controls.

As full-dose psychedelics appear to aide in the relief of severe, chronic psychiatric conditions (e.g. depression, anxiety, PTSD), milder mental health concerns may plausibly be treated by lower, recurring doses.

This is especially worth considering if certain full-dose outcomes are found to rely on purely pharmacologic mechanisms rather than primarily on phenomenological experiences .

Limiting microdosing research to topics that have been investigated in full-dose research could prematurely overlook unpredicted and potentially distinct microdosing outcomes.

Full-dose research has employed various focal assessments of symptomatology, mood, and personality that are likely applicable to microdosing research, but due to the low doses and lack of perceptual alteration intended in microdosing, other full-dose phenomena, such as ego dissolution and mystical-type experiences, are less relevant to microdosing research.

Instead, as a means of preparing for a broad range of outcomes, the present work solicited open-ended reports of benefits and challenges.

Additionally, as psychedelic substances act on distinct yet overlapping neural receptor sites, it seems plausible that distinct patterns could emerge for different substances.

The present study thus included microdosers who used LSD, psilocybin, or both.

The challenges of full-dose psychedelics

While psychedelics appear to have considerable potential benefits and low physiological risks, full-dose experiences can put participants under considerable psychological risk

. In a survey targeting participants that had at least one challenging experience (“bad trip”) with psilocybin mushrooms, 39% of respondents rated their full-dose experiences as among the top 5 most psychologically difficult/challenging experiences of their lives. Griffiths et al. used both “high” (22 mg/70 kg) and “low” (1 or 3 mg/70 kg) doses of psilocybin as experimental and control conditions, respectively. A dose-response effect could be seen such that in the high-dose condition, 32% of participants reported physiological discomfort whereas only 12% reported the same in the low-dose condition; likewise, 26% reported anxiety in the high-dose condition versus 15% in the low-dose condition.

Delayed-onset headaches are another possible side-effect of full-dose psilocybin.

 

Showing all 7 results

Select your currency
USD United States (US) dollar
EUR Euro